AHCO — AdaptHealth Corp.

Summary of AdaptHealth Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Q3 revenue was $820.3 million, up 1.8% year-over-year, with organic revenue growth of 5.1%.
• Adjusted EBITDA: Reached $170.1 million, an increase of 3.5% from the previous year, with an adjusted EBITDA margin of 20.7%, up 30 basis points.
• Debt Reduction: Reduced net debt by $50 million in Q3, totaling $225 million year-to-date. Net leverage ratio improved to 2.68x, nearing the target of 2.5x.
• Cash Flow: Generated $161.1 million in cash flow from operations and $66.8 million in free cash flow.

2. Strategic Updates and Business Highlights

• Operational Improvements: Completed the implementation of a standard operating model, consolidating from six to four regions, enhancing efficiency.
• Technology Investments: Launched a national contact center and a unified patient services technology platform to improve patient interactions and service quality.
• Capitated Agreements: Announced a new exclusive capitated contract with a large integrated delivery network (IDN), expected to generate significant revenue and improve patient care.
• Segment Performance: Strong growth in Sleep Health (5.7% increase in revenue) and Respiratory Health (7.8% increase), while Diabetes Health showed its first growth since Q1 2024.

3. Forward Guidance and Outlook

• 2025 Guidance: Maintained revenue and adjusted EBITDA guidance, anticipating modestly above the midpoint for revenue and at the lower end for EBITDA due to ongoing investments.
• 2026 Expectations: Projected revenue growth of 6% to 8%, with expectations for improved adjusted EBITDA margins as new capitated contracts ramp up.

4. Bad News, Challenges, or Points of Concern

• Wellness at Home Segment: Experienced a 16% decline in revenue, impacted by divestitures of noncore assets.
• Competitive Pressures: Competitors are securing exclusive agreements with large networks, which could impact market share.
• Investment Risks: Increased expenses related to the new capitated contract may affect short-term profitability.

5. Notable Q&A Insights

• Capitated Contract Transition: There are differing expectations regarding the ramp-up of the new capitated contract compared to competitors. AdaptHealth is taking a conservative approach to ensure infrastructure is in place before patient onboarding.
• Market Dynamics: The company is focused on converting more payers to capitated agreements, emphasizing the benefits of streamlined patient care.
• Diabetes Segment: Improved retention rates and execution in the Diabetes segment are showing positive trends, but the team acknowledges the need for continued stability and growth.
• Regulatory Environment: No significant changes in the frequency of audits related to PAPs and ventilators, indicating a stable regulatory landscape.

Overall, AdaptHealth reported solid financial results with strategic initiatives aimed at enhancing operational efficiency and expanding its market presence through capitated agreements, while also navigating challenges in specific segments and competitive pressures.